Cited by 306Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013

Open access

Lipska, Kasia J., Yao, Xiaoxi, Herrin, Jeph, McCoy, Rozalina G., Ross, Joseph S., Steinman, Michael A., Inzucchi, Silvio E., Gill, Thomas M., Krumholz, Harlan M., Shah, Nilay D.·2017·Diabetes Care

DOI 10.2337/dc16-0985PMC PMC5360291

Open this paper in CoChat — free account

Abstract

OBJECTIVE: To examine temporal trends in utilization of glucose-lowering medications, glycemic control, and rate of severe hypoglycemia among patients with type 2 diabetes (T2DM). RESEARCH DESIGN AND METHODS: Using claims data from 1.66 million privately insured and Medicare Advantage patients with T2DM from 2006 to 2013, we estimated the annual 1) age- and sex-standardized proportion of patients who filled each class of agents; 2) age-, sex-, race-, and region-standardized proportion with hemoglobin A1c (HbA1c) <6%, 6 to <7%, 7 to <8%, 8 to <9%, ≥9%; and 3) age- and sex-standardized rate of severe hypoglycemia among those using medications. Proportions were calculated overall and stratified by age-group (18–44, 45–64, 65–74, and ≥75 years) and number of chronic comorbidities (zero, one, and two or more). RESULTS: From 2006 to 2013, use increased for metformin (from 47.6 to 53.5%), dipeptidyl peptidase 4 inhibitors (0.5 to 14.9%), and insulin (17.1 to 23.0%) but declined for sulfonylureas (38.8 to 30.8%) and thiazolidinediones (28.5 to 5.6%; all P < 0.001). The proportion of patients with HbA1c <7% declined (from 56.4 to 54.2%; P < 0.001) and with HbA1c ≥9% increased (9.9 to 12.2%; P < 0.001). Glycemic control varied by age and was poor among 23.3% of the youngest and 6.3% of the oldest patients in 2013. The overall rate of severe hypoglycemia remained the same (1.3 per 100 person-years; P = 0.72), declined modestly among the oldest patients (from 2.9 to 2.3; P < 0.001), and remained high among those with two or more comorbidities (3.2 to 3.5; P = 0.36). CONCLUSIONS: During the recent 8-year period, the use of glucose-lowering drugs has changed dramatically among patients with T2DM. Overall glycemic control has not improved and remains poor among nearly a quarter of the youngest patients. The overall rate of severe hypoglycemia remains largely unchanged.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/dc16-0985

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citation
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citation
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Self-citation
Economic Costs of Diabetes in the U.S. in 2012
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc12-2625 · Cited by 2,227
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
The National Committee for Quality Assurance
Iglehart, J. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609263351322 · Cited by 1,826

Show all 44 references

Research works printed but not linked: 1

2015, Diabetes Care, 38, S1

Sorted by citations

Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001052 · Cited by 5,987
Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Cheng, S., Delling, F. N., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000950 · Cited by 5,784
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Trends in diabetes treatment and control in U.S. adults, 1999-2018
Fang, M., Wang, D., Coresh, J., & Selvin, E. (2021) · New England Journal of Medicine · doi:10.1056/nejmsa2032271 · Cited by 690
Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016)
Esteghamati, A., Larijani, B. A., Aghajani, M. H., Ghaemi, F., Kermanchi, J., Shahrami, A., Saadat, M., Nasli‐Esfahani, E., Ganji, M., Noshad, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13379-z · Cited by 315
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
Vaccaro, O., Masulli, M., Nicolucci, A., Bonora, E., Del Prato, S., Maggioni, A. P., Rivellese, A. A., Squatrito, S., Giorda, C. B., Sesti, G., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30317-0 · Cited by 292
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
Yun, J.-S., & Ko, S.-H. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154838 · Cited by 292
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 276
Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes
Montvida, O., Shaw, J., Atherton, J. J., Stringer, F., & Paul, S. K. (2018) · Diabetes Care · doi:10.2337/dc17-1414 · Cited by 250
Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies
Silbert, R., Salcido-Montenegro, A., Rodriguez-Gutierrez, R., Katabi, A., & McCoy, R. G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1018-0 · Cited by 229
Self-citation
Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014
Carls, G., Huynh, J., Tuttle, E., Yee, J., & Edelman, S. V. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0280-5 · Cited by 228
The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes
Lee, A. K., Warren, B., Lee, C. J., McEvoy, J. W., Matsushita, K., Huang, E. S., Sharrett, A. R., Coresh, J., & Selvin, E. (2018) · Diabetes Care · doi:10.2337/dc17-1669 · Cited by 226
Diabetes and Aging: unique considerations and goals of care
Kalyani, R. R., Golden, S. H., & Cefalu, W. T. (2017) · Diabetes Care · doi:10.2337/dci17-0005 · Cited by 226
Burden of Illness in Type 2 Diabetes Mellitus
Cannon, A., Handelsman, Y., HEILE, M. K., & Shannon, M. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.9-a.s5 · Cited by 226
Hypoglycemia in diabetes: An update on pathophysiology, treatment, and prevention
Nakhleh, A., & Shehadeh, N. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i12.2036 · Cited by 191
Diagnosis and Treatment of Type 2 Diabetes in Adults
Kalyani, R. R., Neumiller, J. J., Maruthur, N. M., & Wexler, D. J. (2025) · JAMA · doi:10.1001/jama.2025.5956 · Cited by 145
Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal Diabetes Register, status 2017
Dedov, I. I., Shestakova, M. V., Vikulova, O. K., Zheleznyakova, A. V., & Исаков, М. А. (2018) · Diabetes Mellitus · doi:10.14341/dm9686 · Cited by 150
Association of cumulative multimorbidity, glycemic control, and medication use with hypoglycemia-related emergency department visits and hospitalizations among adults with diabetes
McCoy, R. G., Lipska, K. J., Van Houten, H. K., & Shah, N. D. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.19099 · Cited by 141
Self-citation
Long-Term Weight Loss Strategies for Obesity
Kheniser, K., Saxon, D. R., & Kashyap, S. R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab091 · Cited by 139
Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data
Dennis, J., Henley, W., Weedon, M. N., Lonergan, M. E., Rodgers, L. R., Jones, A. G., Hamilton, W. T., Sattar, N. A., Janmohamed, S. G., Holman, R. R., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0344 · Cited by 135
Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study
McCoy, R. G., Dykhoff, H. J., Sangaralingham, L., Ross, J. S., Karaca-Mandic, P., Montori, V. M., & Shah, N. D. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0213 · Cited by 122
Self-citation
Do sulphonylureas still have a place in clinical practice?
Khunti, K., Chatterjee, S., Gerstein, H. C., Zoungas, S., & Davies, M. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30025-1 · Cited by 116
Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes
O’Brien, M. J., Karam, S., Wallia, A., Kang, R. H., Cooper, A., Lancki, N., Moran, M. R., Liss, D. T., Prospect, T. A., & Ackermann, R. T. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.6125 · Cited by 116
Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring
Jackson, M. A., Ahmann, A., & Shah, V. N. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0007 · Cited by 106
Ever-Increasing Insulin-Requiring Patients Globally
Garg, S. K., Rewers, A. H., & Aktürk, H. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0101 · Cited by 104
Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta‐Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., & Esposito, K. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012356 · Cited by 102
Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
Schernthaner, G., & Schernthaner-Reiter, M. H. (2018) · Diabetologia · doi:10.1007/s00125-018-4547-9 · Cited by 96
Working smarter not harder: Coupling implementation to de-implementation
Wang, V., Maciejewski, M. L., Helfrich, C. D., & Weiner, B. J. (2017) · Healthcare · doi:10.1016/j.hjdsi.2017.12.004 · Cited by 96
A 5-Decade Analysis of Incidence Trends of Ischemic Stroke After Transient Ischemic Attack
Shahjouei, S., Sadighi, A., Chaudhary, D. P., Li, J., Abedi, V., Holland, N. R., Phipps, M., & Zand, R. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3627 · Cited by 95
Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association
Gabbay, R. A., Kendall, D., Beebe, C., Cuddeback, J. K., Hobbs, T. M., Khan, N. D., Leal, S., Miller, E. M., Novak, L. M., Rajpathak, S. N., et al. (2020) · Clinical Diabetes · doi:10.2337/cd20-0053 · Cited by 91
Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes
Giugliano, D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0951-8 · Cited by 92
Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017
Dennis, J., Henley, W., McGovern, A. P., Farmer, A. A., Sattar, N. A., Holman, R. R., Pearson, E. R., Hattersley, A. T., Shields, B. M., & Jones, A. G. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13687 · Cited by 81
Use of Antihyperglycemic Medications in U.S. Adults: An Analysis of the National Health and Nutrition Examination Survey
Le, P., Chaitoff, A. M., Misra‐Hebert, A. D., Ye, W., Herman, W. H., & Rothberg, M. B. (2020) · Diabetes Care · doi:10.2337/dc19-2424 · Cited by 85
Association of initiation of basal insulin analogs vs Neutral Protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes
Lipska, K. J., Parker, M. M., Moffet, H. H., Huang, E. S., & Karter, A. J. (2018) · JAMA · doi:10.1001/jama.2018.7993 · Cited by 76
Self-citation
Efficacy of Real-Time Continuous Glucose Monitoring to Improve Effects of a Prescriptive Lifestyle Intervention in Type 2 Diabetes: A Pilot Study
Taylor, P. J., Thompson, C. H., Luscombe‐Marsh, N. D., Wycherley, T. P., Wittert, G., & Brinkworth, G. D. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0572-z · Cited by 76
Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a glp-1ra or to basal insulin plus an SGLT2 inhibitor: Beyond, a randomized, pragmatic trial
Giugliano, D., Longo, M., Caruso, P., Di Fraia, R., Scappaticcio, L., Gicchino, M., Petrizzo, M., Bellastella, G., Maiorino, M. I., & Esposito, K. (2021) · Diabetes Care · doi:10.2337/dc20-2623 · Cited by 69
Sociodemographic, clinical, and treatment-related factors associated with hyperglycemic crises among adults with type 1 or type 2 diabetes in the US from 2014 to 2020
McCoy, R. G., Galindo, R. J., Swarna, K. S., Van Houten, H. K., O’Connor, P. J., Umpierrez, G. E., & Shah, N. D. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.23471 · Cited by 69
Self-citation
Decreasing incidence of pharmacologically and non-pharmacologically treated type 2 diabetes in Norway: a nationwide study
Ruiz, P. L., Stene, L. C., Bakken, I. J., Håberg, S. E., Birkeland, K. I., & Gulseth, H. L. (2018) · Diabetologia · doi:10.1007/s00125-018-4681-4 · Cited by 66
Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk
Giugliano, D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2018) · Endocrine · doi:10.1007/s12020-017-1517-9 · Cited by 62
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial
Aroda, V. R., González-Galvez, G., Grøn, R., Halladin, N., Haluzík, M., Jermendy, G., Kok, A., Őrsy, P., Sabbah, M., Sesti, G., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30184-6 · Cited by 68
Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998–2013: A Retrospective Cohort Study
Zhong, V. W., Juhaeri, J., Cole, S. R., Kontopantelis, E., Shay, C. M., Gordon‐Larsen, P., & Mayer‐Davis, E. J. (2017) · Diabetes Care · doi:10.2337/dc16-2680 · Cited by 62
Effect of Nutrition on Statural Growth
Gat‐Yablonski, G., & Luca, F. D. (2017) · Hormone Research in Paediatrics · doi:10.1159/000456547 · Cited by 61
Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios
Peralta, F. G., Abreu, C., Rodríguez, S. G., Barranco, R. J., & Umpierrez, G. E. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0488-z · Cited by 63
The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents
Colagiuri, S., Matthews, D. R., Leiter, L. A., Chan, S. P., Sesti, G., & Marre, M. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.028 · Cited by 59
Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment
Beran, D., Ewen, M. A., Lipska, K. J., Hirsch, I. B., & Yudkin, J. S. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1019-z · Cited by 54
Self-citation
Quantifying the Value of Orally Delivered Biologic Therapies: A Cost-Effectiveness Analysis of Oral Semaglutide
Abramson, A., Halperin, F., Kim, J., & Traverso, G. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.04.022 · Cited by 54
Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005–2007 and 2015–2017
Zhou, X., Shrestha, S. S., Shao, H., & Zhang, P. (2020) · Diabetes Care · doi:10.2337/dc19-2273 · Cited by 54
A Review of Fibraurea tinctoria and Its Component, Berberine, as an Antidiabetic and Antioxidant
Purwaningsih, I., Maksum, I. P., Sumiarsa, D., & Sriwidodo, S. (2023) · Molecules · doi:10.3390/molecules28031294 · Cited by 63
Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope
Giugliano, D., Meier, J. J., & Esposito, K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13629 · Cited by 52
Expert panel guidance and narrative review of treatment simplification of complex insulin regimens to improve outcomes in type 2 diabetes
Jude, E. B., Malecki, M. T., Gomez Huelgas, R., Prazny, M., Snoek, F., Tankova, T., Giugliano, D., & Khunti, K. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01222-2 · Cited by 52
Paradox of glycemic management: multimorbidity, glycemic control, and high-risk medication use among adults with diabetes
McCoy, R. G., Lipska, K. J., Van Houten, H. K., & Shah, N. D. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001007 · Cited by 51
Self-citation
Type 2 diabetes in general practice in Norway 2005–2014: moderate improvements in risk factor control but still major gaps in complication screening
Bakke, Å., Cooper, J. G., Thue, G., Skeie, S., Carlsen, S., Dalen, I., Løvaas, K. F., Madsen, T. V., Oord, E. R., Berg, T. J., et al. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000459 · Cited by 49
The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study
Morton, J. I., Ilomäki, J., Magliano, D. J., & Shaw, J. E. (2020) · Diabetologia · doi:10.1007/s00125-020-05304-3 · Cited by 51
Antidiabetic Activity of Widely Used Medicinal Plants in the Sri Lankan Traditional Healthcare System: New Insight to Medicinal Flora in Sri Lanka
Wasana, K. G. P., Attanayake, A. P., Jayatilaka, K. A. P. W., & Weerarathna, T. P. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6644004 · Cited by 50
Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
Grunberger, G. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0853-8 · Cited by 51
Continuous Glucose Monitoring with Multiple Daily Insulin Treatment: Outcome Studies
McGill, J. B., & Ahmann, A. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0090 · Cited by 49
Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
Giugliano, D., Longo, M., Scappaticcio, L., Caruso, P., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01213-w · Cited by 48
Insulin therapy, weight gain and prognosis
Hodish, I. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13367 · Cited by 48
Multimorbidity patterns, polypharmacy and their association with liver and kidney abnormalities in people over 65 years of age: a longitudinal study
Villén, N., Guisado‐Clavero, M., Fernández‐Bertolín, S., Troncoso‐Mariño, A., Boreu, Q. F., Amado, E., Pons‐Vigués, M., Roso‐Llorach, A., & Violán, C. (2020) · BMC Geriatrics · doi:10.1186/s12877-020-01580-1 · Cited by 49
Trends in Glucose-Lowering Drug Use, Glycemic Control, and Severe Hypoglycemia in Adults With Diabetes in Hong Kong, 2002–2016
Yang, A., Wu, H., Lau, E. S. H., Ronald, C. W., Kong, A. P. S., So, W. Y., Luk, A. O. Y., Chan, J. C. N., & Chow, E. (2020) · Diabetes Care · doi:10.2337/dc20-0260 · Cited by 47
Use and discontinuation of insulin treatment among adults aged 75 to 79 years with type 2 diabetes
Weiner, J. Z., Gopalan, A., Mishra, P., Lipska, K. J., Huang, E. S., Laiteerapong, N., Karter, A. J., & Grant, R. W. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.3759 · Cited by 47
Self-citation
Is there evidence of potential overtreatment of glycaemia in elderly people with type 2 diabetes? Data from the GUIDANCE study
Muller, N., Khunti, K. K., Kuß, O., Lindblad, U., Nolan, J. J., Rutten, G. E. H. M., Trento, M., Porta, M., Roth, J., Charpentier, G., et al. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0939-9 · Cited by 44
Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon
Thieu, V. T., Mitchell, B. D., Varnado, O. J., & Frier, B. M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13941 · Cited by 45
S odium‐glucose co‐transporter‐2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta‐analysis
Giugliano, D., Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., & Esposito, K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14374 · Cited by 42
Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence
Leonard, C. E., Hennessy, S., Han, X., Siscovick, D. S., Flory, J., & Deo, R. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.04.003 · Cited by 43
Trends in the Degree of Control and Treatment of Cardiovascular Risk Factors in People With Type 2 Diabetes in a Primary Care Setting in Catalonia During 2007–2018
Mata‐Cases, M., Vlacho, B., Real, J., Puig-Treserra, R., Bundó, M., Franch‐Nadal, J., & Mauricio, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.810757 · Cited by 43
Laughter yoga as an enjoyable therapeutic approach for glycemic control in individuals with type 2 diabetes: A randomized controlled trial
Hirosaki, M., Ohira, T., Wu, Y., Eguchi, E., Shirai, K., Imano, H., Funakubo, N., Nishizawa, H., Katakami, N., Shimomura, I., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1148468 · Cited by 47
Glycaemic control in type 2 diabetes patients and its predictors: a retrospective database study at a tertiary care diabetes centre in Ningbo, China
Li, J., Chattopadhyay, K., Xu, M., Chen, Y., Hu, F., Chu, J., & Li, L. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019697 · Cited by 43
Global burden of hypoglycaemia-related mortality in 109 countries, from 2000 to 2014: an analysis of death certificates
Zaccardi, F., Dhalwani, N. N., Webb, D. R., Davies, M. J., & Khunti, K. (2018) · Diabetologia · doi:10.1007/s00125-018-4626-y · Cited by 41
Glycaemic control in patients with type 2 diabetes initiating second‐line therapy: Results from the global DISCOVER study programme
Khunti, K., Chen, H., Cid‐Ruzafa, J., Fenici, P., Gomes, M. B., Hammar, N., Ji, L., Kosiborod, M., Pocock, S., Shestakova, M. V., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13866 · Cited by 42
The impact of training healthcare professionals’ communication skills on the clinical care of diabetes and hypertension: a systematic review and meta-analysis
Yao, M., Zhou, X., Xu, Z., Lehman, R., Haroon, S. M., Jackson, D., & Cheng, K. K. (2021) · BMC Family Practice · doi:10.1186/s12875-021-01504-x · Cited by 45
Evaluation of clinical and antidiabetic treatment characteristics of different sub-groups of patients with type 2 diabetes: Data from a Mediterranean population database
Mata‐Cases, M., Franch‐Nadal, J., Real, J., Vlacho, B., Gómez‐García, A., & Mauricio, D. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.02.003 · Cited by 40
Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes
Inzucchi, S. E. (2017) · Diabetes Care · doi:10.2337/dc16-2372 · Cited by 42
Self-citation
Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus
Feng, M., Lv, H., Xu, X., Wang, J., Lyu, W., & Fu, S. (2019) · Medicine · doi:10.1097/md.0000000000016575 · Cited by 40
Glucose-lowering drug use, glycemic outcomes, and severe hypoglycemia: 18-Year trends in 0·9 million adults with Diabetes in Hong Kong (2002–2019)
Yang, A., Wu, H., Lau, E. S. H., Zhang, X., Shi, M., Fan, B., Ronald, C. W., Kong, A. P. S., Luk, A. O. Y., Chan, J. C. N., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100509 · Cited by 37
What's Wrong with This Picture? A Critical Review of Current Centers for Medicare & Medicaid Services Coverage Criteria for Continuous Glucose Monitoring
Galindo, R. J., Parkin, C. G., Aleppo, G., Carlson, A. L., Kruger, D. F., Levy, C. J., Umpierrez, G. E., & McGill, J. B. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0107 · Cited by 38
Exposure to Night-Time Traffic Noise, Melatonin-Regulating Gene Variants and Change in Glycemia in Adults
Eze, I. C., Imboden, M., Foraster, M., Schaffner, E., Kumar, A., Vienneau, D., Héritier, H., Rudzik, F., Thiesse, L., Pieren, R., et al. (2017) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph14121492 · Cited by 35
A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products
Nuffer, W. A., Guesnier, A., & Trujillo, J. M. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817752315 · Cited by 33
Illness Perceptions, Self-efficacy, and Self-reported Medication Adherence in Persons Aged 50 and Older With Type 2 Diabetes
Kim, H., Sereika, S. M., Lingler, J. H., Albert, S. M., & Bender, C. M. (2020) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000675 · Cited by 31
Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia
Leonard, C. E., Brensinger, C. M., Aquilante, C. L., Bilker, W. B., Boudreau, D. M., Deo, R., Flory, J., Gagne, J. J., Mangaali, M. J., & Hennessy, S. (2018) · Diabetes Care · doi:10.2337/dc17-0294 · Cited by 31
A crise financeira e a saúde: o caso do município do Rio de Janeiro, Brasil
O’Dwyer, G., Graever, L., Britto, F. A., de Menezes, T. A., & Konder, M. T. (2019) · Ciência & Saúde Coletiva · doi:10.1590/1413-812320182412.23212019 · Cited by 31
2018 Health Care & Education Presidential Address: The American Diabetes Association in the Era of Health Care Transformation
Hill-Briggs, F. (2019) · Diabetes Care · doi:10.2337/dci18-0051 · Cited by 30
A Clinical Perspective of the Multifaceted Mechanism of Metformin in Diabetes, Infections, Cognitive Dysfunction, and Cancer
Chow, E., Yang, A., Chung, C. H. L., & Chan, J. C. N. (2022) · Pharmaceuticals · doi:10.3390/ph15040442 · Cited by 30
Safety and Efficacy of Inpatient Diabetes Management with Non-insulin Agents: an Overview of International Practices
Galindo, R. J., Dhatariya, K., Peralta, F. G., & Umpierrez, G. E. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01464-1 · Cited by 32
Multimorbidity, Polypharmacy, Severe Hypoglycemia, and Glycemic Control in Patients Using Glucose-Lowering Drugs for Type 2 Diabetes: A Retrospective Cohort Study Using Health Insurance Claims in Japan
Koto, R., Nakajima, A., Miwa, T., & Sugimoto, K. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01421-5 · Cited by 30
Diabetes Distress and Glycemic Control in Type 2 Diabetes: Mediator and Moderator Analysis of a Peer Support Intervention
Mizokami‐Stout, K., Choi, H., Richardson, C. R., Piatt, G., & Heisler, M. (2021) · JMIR Diabetes · doi:10.2196/21400 · Cited by 28
Sex-specific associations between diabetes and dementia: the role of age at onset of disease, insulin use and complications
Zhou, C., Dong, C., Xie, Z., Hao, W., Fu, C., Sun, H., & Zhu, D. (2023) · Biology of Sex Differences · doi:10.1186/s13293-023-00491-1 · Cited by 29
Association of metformin and depression in patients with type 2 diabetes
Yu, H., Yang, R., Wu, J., Wang, S., Qin, X., Wu, T., Hu, Y., & Wu, Y. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.015 · Cited by 26
Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes
Garry, E. M., Buse, J. B., Lund, J. L., Pate, V., & Stürmer, T. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13049 · Cited by 25
Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes
Gamble, J., Donnan, J. R., Chibrikov, E., Twells, L., Midodzi, W. K., & Majumdar, S. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-33483-y · Cited by 24
The Future of Clinical Trial Design: The Transition from Hard Endpoints to Value-Based Endpoints
Kruizinga, M. D., Stuurman, F. E., Groeneveld, G. J., & Cohen, A. F. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_302 · Cited by 26
Changes in Antidiabetic Drug Prescription and Glycemic Control Trends in Elderly Patients with Type 2 Diabetes Mellitus from 2005-2013: An Analysis of the National Center Diabetes Database (NCDD-03)
Yamamoto‐Honda, R., Takahashi, Y., Mori, Y., Yamashita, S., Yoshida, Y., Kawazu, S., Iwamoto, Y., Kajio, H., Yanai, H., Mishima, S., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.9481-17 · Cited by 25
The Final Frontier in Diabetes Care: Implementing Research in Real-World Practice
Green, J. B., Crowley, M. J., Sathish, T., Maruthur, N. M., & Oldenburg, B. F. (2024) · Diabetes Care · doi:10.2337/dci24-0001 · Cited by 31
Continuous Glucose Monitoring (CGM) Is a Tool, Not a Reward: Unjustified Insurance Coverage Criteria Limit Access to CGM
Kruger, D. F., & Anderson, J. E. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0193 · Cited by 27
Hypoglycemia communication in primary care visits for patients with diabetes
Pilla, S. J., Park, J., Schwartz, J. L., Albert, M. C., Ephraim, P. L., Boulware, L. E., Mathioudakis, N. N., Maruthur, N. M., Beach, M. C., & Greer, R. C. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06385-x · Cited by 23
The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm
Mohan, V., Cooper, M. E., Matthews, D. R., & Khunti, K. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0573-y · Cited by 25
Comparison of Mortality and Major Cardiovascular Events Among Adults With Type 2 Diabetes Using Human vs Analogue Insulins
Neugebauer, R. S., Schroeder, E. B., Reynolds, K., Schmittdiel, J. A., Loes, L., Dyer, W., DESAI, J. R., Vazquez‐Benitez, G., Ho, P. M., Anderson, J. P., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.18554 · Cited by 22
Lower mean blood glucose during short‐term intensive insulin therapy is associated with long‐term glycemic remission in patients with newly diagnosed type 2 diabetes: Evidence‐based recommendations for standardization
Liu, L., Liu, J., Xu, L., Ke, W., Wan, X., Li, H., He, X., Wang, L., Cao, X., Xiao, H., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12782 · Cited by 24
Clinical Benefits Over Time Associated with Use of V-Go Wearable Insulin Delivery Device in Adult Patients with Diabetes: A Retrospective Analysis
SUTTON, D. R., Higdon, C., NIKKEL, C. C., & Hilsinger, K. A. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0703-3 · Cited by 22

Authors: Lipska, K. J., Yao, X., Herrin, J., McCoy, R. G., Ross, J. S., Steinman, M. A., Inzucchi, S. E., Gill, T. M., Krumholz, H. M., & Shah, N. D.
Affiliations: Yale University (US)
Mayo Clinic (US)
Yale New Haven Hospital (US)
University of California, San Francisco (US)
Corresponding author: Lipska, Kasia J.
ORCID: Lipska, Kasia J.
Yao, Xiaoxi
Herrin, Jeph
McCoy, Rozalina G.
Ross, Joseph S.
Steinman, Michael A.
Inzucchi, Silvio E.
Gill, Thomas M.
Krumholz, Harlan M.
Shah, Nilay D.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2016-09-22
Volume: 40
Issue: 4
Pages: 468-475
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dc16-0985
PMC: PMC5360291
OpenAlex: W2523617397
Semantic Scholar: 6b4700268ff332c2ae444b5f7bdbed9cf6cd276e
Cited by: 306
References: 44
Citations by year: 2026: 4 · 2025: 13 · 2024: 22 · 2023: 40 · 2022: 34 · 2021: 37 · 2020: 44 · 2019: 40 · 2018: 44 · 2017: 26 · 2016: 1
FWCI: 37.16
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.diabetesjournals.org/content/license (vor, 180 d)
Locations: Diabetes Care (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Center for Advancing Translational Sciences (UL1 TR000135)
National Institute on Aging (K23AG048359, P30AG021342, K24AG049057, P30AG044281, K07AG3587)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: type 2 diabetes, glucose-lowering medications, drug use trends, glycemic control, HbA1c, severe hypoglycemia, metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, insulin, comorbidities, Medicare Advantage
MeSH terms: Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Drug Utilization, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Retrospective Studies, Sulfonylurea Compounds, Comorbidity, Logistic Models, Thiazolidinediones, Dipeptidyl-Peptidase IV Inhibitors, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks